Furthermore, a 3-year follow-up of NAFLD subject outcome indicated that serum FGF21 level might be a clinically-relevant disease biomarker, suggesting its potential for monitoring response to therapy [17]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.